Takeda concludes original agreement to outsource drug development

Japan-based Takeda announced on an interesting press release it will outsource the development of drugs targeting pediatric epilepsy to US-based Ovid Therapeutics. The agreement mainly provides for the development of TAK-935, an investigational drug inhibiting the enzyme cholesterol 24-hydroxylase (CH24H), considered responsible for the onset of the disease symptoms (Dravet syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis Complex). The product has already been tested in a Phase I trial, which has provided relevant information on its tolerability. The next step will be a Phase II trial. The companies will share in the development and commercialization costs (50/50) and, if the product is launched, Ovid will be responsible for the development of the American and European markets, while Takeda for the Asian market. The companies will also share in the profits on a 50/50 basis. In addition, as part of the agreement, Takeda will acquire an ownership share of Ovid, even though the parties have not provided details about the shareholding percentage. The agreement is quite unique if compared with other development agreements within the big pharma and could pave the way for new market development ideas. (Source Takeda)